

Hongyun Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6154949/publications.pdf>

Version: 2024-02-01

87
papers

758
citations

687335

13
h-index

677123

22
g-index

90
all docs

90
docs citations

90
times ranked

896
citing authors

#	ARTICLE	IF	CITATIONS
1	AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2586-2597.	4.1	69
2	Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban “an oral, direct factor Xa inhibitor” in elderly Chinese subjects. <i>Thrombosis and Haemostasis</i> , 2010, 103, 234-241.	3.4	62
3	Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote. <i>Clinical Therapeutics</i> , 2020, 42, 614-624.	2.5	57
4	First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-“Small Cell” Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance. <i>Journal of Thoracic Oncology</i> , 2018, 13, 968-977.	1.1	50
5	The Pharmacokinetics, Pharmacodynamics, and Tolerability of Liraglutide, a Once-Daily Human GLP-1 Analogue, After Multiple Subcutaneous Administration in Healthy Chinese Male Subjects. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1620-1627.	2.0	23
6	Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 137, 78-83.	2.8	23
7	Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects. <i>Frontiers in Pharmacology</i> , 2018, 9, 1316.	3.5	22
8	Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 276-284.	6.1	20
9	Development and validation of a UPLC-“MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma. <i>Biomedical Chromatography</i> , 2018, 32, e4365.	1.7	19
10	Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 948-959.	2.0	16
11	Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLYS/APRIL fusion protein, in patients with rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 41-52.	2.4	14
12	Development and validation of a rapid and sensitive UPLC-“MS/MS method for quantification of kukoamine B in human plasma: Application to a clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 132, 1-6.	2.8	14
13	Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. <i>Frontiers in Pharmacology</i> , 2018, 9, 991.	3.5	14
14	Development of an UPLC-“MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 139, 205-214.	2.8	13
15	Simultaneous determination of remimazolam and its carboxylic acid metabolite in human plasma using ultra-performance liquid chromatography-“tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 976-977, 78-83.	2.3	12
16	In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 157, 105618.	4.0	12
17	Pharmacokinetics and Safety of Subcutaneous Pasireotide and Intramuscular Pasireotide Long-acting Release in Chinese Male Healthy Volunteers: A Phase I, Single-center, Open-label, Randomized Study. <i>Clinical Therapeutics</i> , 2014, 36, 1196-1210.	2.5	11
18	Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-“small cell lung cancer. <i>Cancer</i> , 2015, 121, 3146-3156.	4.1	11

#	ARTICLE	IF	CITATIONS
19	A validated UPLC-MS/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 170, 112-123.	2.8	11
20	Pharmacokinetics of Single Ascending Doses and Multiple Doses of 20(S)-Ginsenoside Rg3 in Chinese Healthy Volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 845-853.	1.6	10
21	Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2547-2558.	2.4	10
22	Intrapulmonary concentration of levofloxacin in patients with idiopathic pulmonary fibrosis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2014, 28, 49-52.	2.6	9
23	Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 816-826.	2.0	9
24	Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses. <i>Xenobiotica</i> , 2016, 46, 1133-1141.	1.1	9
25	Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study. <i>Bioanalysis</i> , 2018, 10, 863-875.	1.5	9
26	Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2019, 39, 643-651.	2.2	9
27	Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects. <i>Pharmacotherapy</i> , 2015, 35, 586-599.	2.6	8
28	In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1373-1385.	3.5	8
29	Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2015, 40, 203-208.	1.6	7
30	Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending-dose and Multiple-dose, Parallel-group Study. <i>Clinical Therapeutics</i> , 2016, 38, 348-357.	2.5	7
31	Validation and Application of an LC-MS-MS Method for the Determination of Ceftizoxime in Human Serum and Urine. <i>Journal of Chromatographic Science</i> , 2016, 54, 713-719.	1.4	7
32	Development and validation of a UPLC-MS/MS method for simultaneous determination of fotaligiptin and its two major metabolites in human plasma and urine. <i>Bioanalysis</i> , 2017, 9, 381-393.	1.5	7
33	Odanacatib Pharmacokinetics Comparison Between Chinese and Non-Chinese Postmenopausal Women. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 744-750.	1.6	7
34	A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imiglitin, its five metabolites and aloglitin in human plasma and urine and its application to a multiple-dose pharmacokinetic study. <i>Biomedical Chromatography</i> , 2018, 32, e4324.	1.7	7
35	A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 136, 104942.	4.0	7
36	The progress of chemokines and chemokine receptors in autism spectrum disorders. <i>Brain Research Bulletin</i> , 2021, 174, 268-280.	3.0	7

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: A five-way crossover study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1823-1828.	2.8	6
38	Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus. <i>Clinical Drug Investigation</i> , 2016, 36, 889-902.	2.2	6
39	Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1068-1069, 33-40.	2.3	6
40	An UPLC-MS/MS method to determine CT-707 and its two metabolites in plasma of ALK-positive advanced non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 153, 1-8.	2.8	6
41	Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. <i>Biomedical Chromatography</i> , 2019, 33, e4420.	1.7	6
42	Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BlyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 159, 105704.	4.0	6
43	Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2016, 36, 463-470.	2.2	5
44	Simultaneous determination of roflumilast and its metabolite in human plasma by LC-MS/MS: Application for a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1029-1030, 60-67.	2.3	5
45	A validated UPLC-MS/MS method for the quantitation of an unstable peptide, monocyte locomotion inhibitory factor (MLIF) in human plasma and its application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 157, 75-83.	2.8	5
46	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. <i>Xenobiotica</i> , 2018, 48, 459-466.	1.1	5
47	A validated ultra-HPLC-MS/MS method for determination of honokiol in human plasma and its application to a clinical pharmacokinetic study. <i>Bioanalysis</i> , 2019, 11, 1085-1098.	1.5	5
48	Development of a rapid and sensitive UPLC-MS/MS assay for simultaneous quantitation of Vorolanib and its metabolite in human plasma and application to a pharmacokinetics study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 199, 114034.	2.8	5
49	A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3105-3105.	1.6	5
50	Pharmacokinetics of LBPT and its primary metabolites, as well as tolerability in the first-in-human study. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 100, 87-93.	4.0	4
51	An LC-MS/MS method for quantification of AC0010, a novel mutant-selective epidermal growth factor receptor (EGFR) inhibitor, and its metabolites in human plasma and the application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 141, 9-18.	2.8	4
52	Determination of Isosorbide-5-Mononitrate in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and Its Application to a Bioequivalence Study. <i>Journal of Analytical Methods in Chemistry</i> , 2020, 2020, 1-10.	1.6	4
53	Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 486-493.	1.6	4
54	Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 645130.	3.5	4

#	ARTICLE	IF	CITATIONS
55	LC-MS/MS Method to Simultaneously Determine Six Probe Drugs for CYP450 Isozymes in Human Liver Microsomes. <i>Chromatographia</i> , 2014, 77, 913-922.	1.3	3
56	Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study. <i>Clinical Drug Investigation</i> , 2016, 36, 369-376.	2.2	3
57	A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30 mg in healthy Chinese volunteers. <i>Xenobiotica</i> , 2017, 47, 592-599.	1.1	3
58	Development of a quantitative method for four photocyanine isomers using differential ion mobility and tandem mass spectrometry and its application in a preliminary pharmacokinetics investigation. <i>Journal of Chromatography A</i> , 2018, 1577, 109-119.	3.7	3
59	Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males. <i>Clinical Drug Investigation</i> , 2018, 38, 901-908.	2.2	3
60	Development of an LC-MS/MS method for quantifying two main metabolites of abivertinib in human plasma. <i>Biomedical Chromatography</i> , 2020, 34, e4704.	1.7	3
61	How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)? <i>Clinical Infectious Diseases</i> , 2021, 73, 352-353.	5.8	3
62	Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1169, 122585.	2.3	3
63	Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations. <i>Die Pharmazie</i> , 2009, 64, 323-6.	0.5	3
64	Calcium bioavailability of calcium L-threonate in healthy Chinese subjects measured with stable isotopes (⁴⁴ Ca and ⁴² Ca). <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1121-1126.	1.9	2
65	A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 84-92.	1.6	2
66	Simultaneous determination of imiglitin and its three metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1002, 300-312.	2.3	2
67	Ultra performance liquid chromatography tandem mass spectrometry assay for determination of kukoamine B in human blood and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1031, 8-14.	2.3	2
68	A rapid and sensitive UPLC-MS/MS method for determination of remimazolam and its main metabolite in human urine and its application in clinical urine recovery study. <i>Acta Chromatographica</i> , 2018, 30, 109-113.	1.3	2
69	Simultaneous determination of morphine-3- <i>O</i> -glucuronide, morphine-3- <i>O</i> -glucuronide and morphine in human plasma and urine by ultra-performance liquid chromatography-tandem mass spectrometry: Application to M6G injection pharmacokinetic study. <i>Biomedical Chromatography</i> , 2018, 32, e4066.	1.7	2
70	Metabolites characterization of a novel DPP-4 inhibitor, imiglitin in humans and rats using ultra-high performance liquid chromatography coupled with synapt high-resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 157, 189-200.	2.8	2
71	Evaluation of Therapeutic Equivalence for the Follow-On Version of Intravenously Administered Non-Biological Complex Drugs. <i>Clinical Pharmacokinetics</i> , 2020, 59, 995-1004.	3.5	2
72	Accelerating Development of Benzimidazole-Class Proton Pump Inhibitors: A Mechanism-Based PK/PD Model to Optimize Study Design with Ilaprazole as a Case Drug. <i>Pharmaceutics</i> , 2021, 13, 392.	4.5	2

#	ARTICLE	IF	CITATIONS
73	Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4111-4120.	2.4	2
74	A UPLC-MS/MS method for quantification of 5 α -androst-3 β ,5,6 β -triol in human plasma: development, validation and its application in clinical pharmacokinetic study. <i>Bioanalysis</i> , 2017, 9, 873-885.	1.5	1
75	Simultaneous determination of TPN729 and its five metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 151, 91-105.	2.8	1
76	An ultra HPLC-MS/MS method for quantification of hypidone hydrochloride (YL-0919) and application to a pharmacokinetic study. <i>Bioanalysis</i> , 2019, 11, 1243-1254.	1.5	1
77	CX1003 quantification by ultra-performance LC-MS/MS in human plasma and its application to a pharmacokinetic study in solid tumor patients. <i>Bioanalysis</i> , 2019, 11, 1483-1493.	1.5	1
78	A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 166, 20-29.	2.8	1
79	Simultaneous determination of FLZ and its metabolite (M1) in human plasma and urine by UHPLC-MS/MS: Application to a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 32-40.	2.8	1
80	UHPLC-MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study. <i>Bioanalysis</i> , 2020, 12, 367-378.	1.5	1
81	A UHPLC-MS/MS method to determine FLZ major active metabolites in human plasma: application to a pharmacokinetic study. <i>Bioanalysis</i> , 2020, 12, 583-596.	1.5	1
82	Determination of BPI15086 and its metabolite in human plasma by ultra-high performance liquid chromatography-MS/MS and its application to a pharmacokinetic study. <i>Bioanalysis</i> , 2019, 11, 773-784.	1.5	0
83	Application of LC-MS/MS method for determination of dihydroartemisin in human plasma in a pharmacokinetic study. <i>Bioanalysis</i> , 2020, 12, 1635-1646.	1.5	0
84	Development and validation of a UPLC-MS/MS method for simultaneous determination of LBPT and its metabolites in human plasma. <i>Bioanalysis</i> , 2020, 12, 211-220.	1.5	0
85	Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 160, 105752.	4.0	0
86	A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 387-396.	2.3	0
87	Development and validation of a high performance liquid chromatography-MS/MS method for determination of SOMCL-15-290 in a first-in-human study. <i>Bioanalysis</i> , 2022, , .	1.5	0